| Symbol | ARQT |
|---|---|
| Name | ARCUTIS BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3027 TOWNSGATE ROAD,SUITE 300, WESTLAKE VILLAGE, California, 91361, United States |
| Telephone | +1 805 418-5006 |
| Fax | — |
| — | |
| Website | https://www.arcutis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The companys lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. Additional info from NASDAQ: |
New Form S-8 - Arcutis Biotherapeutics, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001787306-26-000033 <b>Size:</b> 784 KB
Read moreNew Form DEFA14A - Arcutis Biotherapeutics, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001787306-26-000030 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Arcutis Biotherapeutics, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001787306-26-000028 <b>Size:</b> 3 MB
Read moreArcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Read moreDirector Welgus Howard G. 🔴 sold 10.0K shares of Arcutis Biotherapeutics, Inc. (ARQT) at $23.88 Transaction Date: Apr 01, 2026 | Filing ID: 023736
Read more📋 Howard Welgus (Director) plans to sell 10K shares of Arcutis Biotherapeutics, Inc. (at $23.88 each, total $239K) Filed: Apr 01, 2026 | ID: 022781
Read moreArcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Read moreArcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Read moreNew Form SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000405 <b>Size:</b> 7 KB
Read moreArcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07105254 | An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of … | Phase2 | Non-segmental Vitiligo | Recruiting | 2025-08-01 | 2026-06-15 | ClinicalTrials.gov |
| NCT06998056 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2… | Phase2 | Atopic Dermatitis (Eczema) | Completed | 2025-06-09 | 2025-12-04 | ClinicalTrials.gov |
| NCT05028582 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | Phase3 | Scalp Psoriasis | Completed | 2021-08-24 | 2022-06-03 | ClinicalTrials.gov |
| NCT04845620 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatit… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-04-07 | 2023-06-01 | ClinicalTrials.gov |
| NCT04804605 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Manageme… | Phase3 | Atopic Dermatitis Eczema | Completed | 2021-02-25 | 2024-05-28 | ClinicalTrials.gov |
| NCT04378569 | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema | Phase1 | Chronic Hand Eczema | Completed | 2020-04-20 | 2021-02-24 | ClinicalTrials.gov |
| NCT04279119 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults … | Phase1 | Plaque Psoriasis | Completed | 2020-03-10 | 2021-03-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | DRUG | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-234 | BIOLOGICAL | Phase PHASE1 | Atopic Dermatitis (AD) | RECRUITING | NCT07453602 |
| ARQ-154 Foam 0.3% | DRUG | Phase PHASE1 | Psoriasis | RECRUITING | NCT07340216 |
| Roflumilast topical 0.3% foam | DRUG | Phase PHASE2 | Non-segmental Vitiligo | RECRUITING | NCT07105254 |
| Topical roflumilast 0.3% foam | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | RECRUITING | NCT07077902 |
| Vehicle Foam | DRUG | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| Roflumilast Foam | DRUG | Phase PHASE3 | Seborrheic Dermatitis | COMPLETED | NCT04973228 |
| NB-UVB phototherapy sham treatment | DEVICE | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| NB-UVB phototherapy active treatment | DEVICE | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-252 Vehicle cream | DRUG | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04804605 |
| Vehicle cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| Roflumilast Cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773600 |
| ARQ-151 cream 0.3% | DRUG | Phase PHASE2 | Psoriasis | COMPLETED | NCT04746911 |
| ARQ-154 | DRUG | Phase PHASE2 | Seborrheic Dermatitis | COMPLETED | NCT04445987 |
| ARQ-252 Vehicle Cream | DRUG | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.1% | DRUG | Phase PHASE1 | Chronic Hand Eczema | COMPLETED | NCT04378569 |
| ARQ-252 cream 0.3% | DRUG | Phase PHASE2 | Vitiligo | TERMINATED | NCT04811131 |
| Topical roflumilast | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04286607 |
| ARQ-151- cream 0.3% | DRUG | Phase PHASE1 | Plaque Psoriasis | COMPLETED | NCT04279119 |
| ARQ-151 0.3% cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| Roflumilast 0.3% cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211363 |
| ARQ-151 cream 0.05% | DRUG | Phase PHASE2 | Atopic Dermatitis (Eczema) | COMPLETED | NCT06998056 |
| Roflumilast foam 0.3% | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| Vehicle foam | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04128007 |
| Roflumilast Foam 0.3% | DRUG | Phase PHASE3 | Scalp Psoriasis | COMPLETED | NCT05028582 |
| Roflumilast Cream 0.05% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| Roflumilast | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03764475 |
| Vehicle Cream | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04845620 |
| Roflumilast Cream 0.15% | DRUG | Phase PHASE3 | Atopic Dermatitis Eczema | COMPLETED | NCT04773587 |
| Roflumilast Cream 0.3% | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT03638258 |
| ARQ-151 vehicle cream | DRUG | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT04211389 |
| ARQ-151 cream 0.15% | DRUG | Phase PHASE1 | Atopic Dermatitis (Eczema) | COMPLETED | NCT04156191 |
| ARQ-151 cream 0.5% | DRUG | Phase PHASE1 | Psoriasis | COMPLETED | NCT03392168 |